AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00469209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 100 mg/m2 by vein days -4,-3, over 30 minutes
Study NCT00469209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C (Ascorbic Acid)
Description: 1000 mg once a day through the vein for 7 days.
Study NCT00288054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2.
Study NCT00288054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications.
Study NCT00531492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TK as soon as possible within 24 hours after birth
Description: Start TK as soon as possible within 24 hours after birth
Study NCT00531492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
Study NCT00915538 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pMDI budesonide/formotrol 160/4.5 is in group 1
Description: The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
Study NCT00286299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic high-intensity interval training (AIT)
Description: The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
Study NCT00286299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer game training (CG)
Description: The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
Study NCT00286299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
Study NCT00695409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00695409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV
Study NCT00695409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00695409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00695409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00695409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00695409 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT04218422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Acupuncture at 5 points on the ears
Study NCT04218422 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture in 2 points for liver and 1 point for stomach
Study NCT01529502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
Study NCT01529502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
Study NCT01529502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO) administration
Description: Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
Study NCT02687997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poligraphy
Description: Sleep study
Study NCT04649658 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prone position
Description: Prone position maintained at least 3 hours/day
Study NCT02653339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qufeng Shengshi Fang and Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Study NCT02653339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qufeng Shengshi Fang and Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Study NCT02653339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD
Study NCT02653339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD
Study NCT02103062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Study NCT00915538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pMDI budesonide/formotrol 160/4.5 is in group 1
Description: The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
Study NCT00915538 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Description: Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
Study NCT00915538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Description: Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
Study NCT00343109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu intracellular domain protein
Description: Given ID
Study NCT00343109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Optional correlative studies
Study NCT00343109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00343109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID
Study NCT00343109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study NCT00343109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic tumor-associated peptide vaccine therapy
Description: Given ID
Study NCT00690430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
Study NCT00690430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
Study NCT01687881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Chiropractic Spinal Manipulative Therapy
Study NCT01687881 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Chiropractic
Description: Sham manipulation
Study NCT04650997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
Study NCT04650997 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Eccentric exercise
Description: Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
Study NCT01090921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone.
Study NCT00742924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT03565822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
Study NCT01838460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual nicotine tablets
Description: 6 mg = 3 tablets
Study NCT01838460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smokeless tobacco
Description: Swedish type moist snuff
Study NCT01856842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography and embolotherapy
Study NCT02533401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Study NCT02533401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Study NCT02533401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Study NCT01422512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study NCT02899806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Written Information
Description: A written information on peridural anesthesia is delivered
Study NCT02899806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Information
Description: A written information on peridural anesthesia is delivered
Study NCT01611740 — intervention group
Intervention type: PROCEDURE
Intervention: Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642
Description: Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships.
Study NCT02843438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fluorescein angiography
Study NCT02843438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dilated fundus examination
Study NCT02843438 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Toxoplasmosis serology
Study NCT02843438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-toxoplasmosis treatment
Study NCT02843438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anti-inflammatory treatments
Study NCT02843438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Puncture in anterior chamber
Study NCT06554119 — intervention group
Intervention type: PROCEDURE
Intervention: Huanlei Huang
Description: tricuspid valve replacement or plasty
Study NCT01320345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg tablet of fenofibrate administered once daily for 36 months.
Study NCT01320345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert lactose placebo
Description: Insert lactose tablet matching active tablet administered once daily for 36 months.
Study NCT01591434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL®
Description: Dressing to be changed as clinically needed or at least every seven days.
Study NCT01591434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Extra™
Description: Dressing to be changed as clinically needed or at least every seven days.
Study NCT01681667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
Study NCT03987711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
Study NCT03987711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
Study NCT03987711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No oral anticoagulation
Description: No oral anticoagulation
Study NCT01789359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blueberry Juice
Description: Dietary intervention
Study NCT03087604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block
Description: Thoracic epidural block with epidural placed with a loss of resistance technique alone.
Study NCT03087604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: Thoracic epidural block with epidural placed with a loss of resistance technique alone.
Study NCT03087604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Nerve stimulation
Description: In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
Study NCT03087604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution For Thoracic epidural block
Description: Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
Study NCT03087604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution For Thoracic epidural block
Description: Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
Study NCT01393899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets twice daily
Study NCT01393899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily
Study NCT02899806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Information
Description: A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
Study NCT03126578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: LEO 32731 is being developed by LEO Pharma.
Study NCT03126578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Benzodiazepine
Study NCT01460706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]DOTATOC
Description: 120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
Study NCT05789459 — intervention group
Intervention type: DEVICE
Intervention: Stapler
Description: Stapler
Study NCT05789459 — intervention group
Intervention type: OTHER
Intervention: Suture
Description: Suture
Study NCT02122146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06664178
Description: Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
Study NCT02122146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06664178
Description: Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
Study NCT02001324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web-based data collection
Study NCT02001324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based data collection
Study NCT02735421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABPO Forte Gel
Description: Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
Study NCT02735421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
Study NCT03086538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
Study NCT03086538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva 100Mg Tablet
Description: Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
Study NCT01752725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiCision®
Study NCT01752725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultracision® Har-monic Scalpel(Ethicon)
Study NCT03770676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium-fortified biscuits
Description: Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
Study NCT01145781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.